[关键词]
[摘要]
糖尿病性黄斑水肿(DME)是糖尿病威胁视力的一种眼部并发症，是成人失明的重要原因。当前，中国有糖尿病患者1.41亿，伴随糖尿病患病人数的增长，DME的发病率也在逐年攀升。现代医学对DME的治疗取得了一定效果，但副作用明显，且有局限性。明目-11是我院眼科临床应用较为广泛的治疗糖尿病视网膜病变的有效方剂，包含了藏花醛、藏红花酸、姜黄素、没食子酸、鞣花酸、山奈酚、香草醛等生物活性成分。明目-11相关实验研究和临床应用报告显示，该药对DME的神经损害、缺血再灌注损伤、炎症、氧化损伤、微血管损害及渗漏等具有保护作用，可延缓糖尿病视网膜病变(DR)的进展。本文从DME的发病机制、明目-11及其活性成分对DME的治疗作用等方面进行论述。
[Key word]
[Abstract]
Diabetic macular edema(DME)is one of the vision-threatening ocular complications of diabetes and is an important cause of blindness in adults. At present, there are 141 million diabetics in China. With the increase of the number of diabetics, the incidence of DME is also increasing year by year. Modern medicine has achieved certain results in the treatment of DME, but the side effects are obvious, and the effectiveness is limited. Mingmu-11 is an effective prescription widely used in the ophthalmology of our hospital. It contains bioactive ingredients such as safranal, crocetin, curcumin, gallic acid, ellagic acid, kaempferol and vanillin. Experimental studies and clinical application reports have shown that Mingmu-11 has a protective effect on nerve damage, ischemia-reperfusion injury, inflammation, oxidative damage, microvascular damage and leakage in the pathogenesis of DME, and it can delay the progression of diabetic retinopathy(DR). The pathogenesis of DME, Mingmu-11 and its active ingredients, and the therapeutic effects on DME are reviewed.
[中图分类号]
[基金项目]
国家自然科学基金项目(No.82160815); 内蒙古自治区科技计划项目(No.2022YFSH0061)
